Thermo Fisher’s Swindon facility specializes in integrated sterile liquid and lyophilized product development and commercial manufacturing, including high potency products and LVP. The Swindon facility offers extensive development and commercial capabilities for sterile dosage forms, including liquid vials, commercial fill finish lines, primary and secondary packaging vials.
The facility has:
Additionally, the facility has extensive complex technology transfer expertise. Its Qualified Persons (QPs) ensure prompt release of bulk products within the European market. Swindon has received regulatory approval from various international regulatory inspection agencies, including MHRA, FDA and the Gulf Co-operation Council
|Early Development||Late dev||Commercial supply|
Four special fill/finish considerations for vaccine production
Once your vaccine is ready for production, there are critical considerations needed in regard to the handling and process for fill/finish. The right choices can help ensure the stability and purity of your vaccine as well as limit unnecessary waste and cost. View the infographic for details on best practices for fill/finish.View Infographic
Challenges and Practical Solutions for Switching to Prefilled Syringes for Injectables
Learn the critical patient benefits and improved outcomes of prefilled syringes, as well as how to select the most appropriate type and how to bridge vials with them.
Switching delivery formats: A lifecycle management strategy for sterile injectables
Switching delivery formats can be an effective strategy to enhance they lifecycle of your drug. This whitepaper provides insight into the benefits and challenges of transferring a therapeutic compound from one aseptic injectable format to another.
Patient-centric sterile injectables: Improving patient experience through formulation and delivery
Join us for an expert panel of biologics experts as we discuss patient-related characteristics that should inform drug product design decisions, product-related characteristics that can be modified to address the needs of the target patient populations and innovative technologies that can be used to address patient needsWatch Webinar